Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Vaughan

Internal Medicine Dalton, MA Medical Doctor

NPI 1730275140 CMS profile 260602

33 North St, Dalton, MA 01226

Open in the dashboard

General payments

$3,104

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Vaughan of Dalton, MA is reported in the CMS Open Payments database as having received $3,104 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $449 19
2024 General $384 17
2023 General $395 20
2022 General $360 21
2021 General $288 18
2020 General $160 9
2019 General $1,068 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Vaughan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Vaughan were reported at $449. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Vaughan Internal Medicine median Middle half National median
2019 $1,068 $159 $48–$570 $163
2020 $160 $119 $33–$402 $114
2021 $288 $135 $37–$521 $132
2022 $360 $141 $42–$496 $149
2023 $395 $149 $45–$519 $160
2024 $384 $154 $47–$537 $164
2025 $449 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $518 34 payments
  2. GlaxoSmithKline, LLC. $334 24 payments
  3. AstraZeneca Pharmaceuticals LP $304 18 payments
  4. AbbVie, Inc. $289 15 payments
  5. Astellas Pharma US Inc $200 8 payments
  6. Amgen Inc. $188 10 payments
  7. Lilly USA, LLC $166 9 payments
  8. Merck Sharp & Dohme Corporation $161 9 payments
  9. Novo Nordisk Inc $156 8 payments
  10. Janssen Pharmaceuticals, Inc $127 8 payments
  11. Other $659 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,020 174 payments
  2. Education $84 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $223 12 payments
  2. COLOGUARD $205 15 payments
  3. CHANTIX $154 11 payments
  4. NURTEC ODT $154 7 payments
  5. Veozah $135 5 payments
  6. Prolia $133 7 payments
  7. XARELTO $127 8 payments
  8. QULIPTA $112 6 payments
  9. UBRELVY $109 6 payments
  10. Ozempic $107 6 payments
  11. Other $2,657 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 191 drugs

Part D claims

16,244

Median for Internal Medicine: 777

Drug cost

$1,303,135

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 359 $282,584
Vyndamax Tafamidis Brand 12 $273,344
Xarelto Rivaroxaban Brand 132 $130,423
Trulicity Dulaglutide Brand 76 $82,256
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 83 $57,452
Januvia Sitagliptin Phosphate Brand 44 $46,746
Spiriva Respimat Tiotropium Bromide Brand 28 $24,830
Farxiga Dapagliflozin Propanediol Brand 29 $23,580
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 34 $18,534
Ozempic Semaglutide Brand 21 $17,416

The 10 drugs with the highest cost, of 191 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$401,149

Of which drugs: $41,455

Medicare patients

1,193

Average age 75

Services billed

6,699

588 women, 605 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 37%
Ischemic heart disease 24%
Diabetes 21%
Osteoporosis 20%
COPD 16%
Atrial fibrillation 15%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 363 363 $29,701
Pcv20 vaccine im 90677 Office 36 36 $10,432
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 11 11 $834
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 16 16 $350

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $78
$78 — —
Nayzilam
  • UCB, Inc. $32
$32 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $25
$25 — —
VRAYLAR
  • AbbVie, Inc. $23
$23 — —
VYNDAQEL
  • PFIZER INC. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record